Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Drops By 18.0%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totalling 29,670,000 shares, a decrease of 18.0% from the May 31st total of 36,180,000 shares. Based on an average daily volume of 3,660,000 shares, the days-to-cover ratio is currently 8.1 days.

BioCryst Pharmaceuticals Trading Up 1.1 %

Shares of BioCryst Pharmaceuticals stock opened at $6.18 on Monday. The company has a 50 day moving average of $5.78 and a 200 day moving average of $5.62. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $7.95.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million for the quarter, compared to analysts’ expectations of $85.62 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 34.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.28) EPS. On average, research analysts predict that BioCryst Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Insider Activity at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Machelle Sanders sold 4,689 shares of the business’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $6.00, for a total value of $28,134.00. Following the transaction, the director now directly owns 27,742 shares in the company, valued at approximately $166,452. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other BioCryst Pharmaceuticals news, Director Steven K. Galson acquired 21,940 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average cost of $5.49 per share, with a total value of $120,450.60. Following the transaction, the director now owns 51,551 shares of the company’s stock, valued at $283,014.99. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Machelle Sanders sold 4,689 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $6.00, for a total transaction of $28,134.00. Following the completion of the transaction, the director now directly owns 27,742 shares in the company, valued at approximately $166,452. The disclosure for this sale can be found here. Over the last quarter, insiders bought 103,601 shares of company stock valued at $596,338. 4.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Quarry LP acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $54,000. Tower Research Capital LLC TRC grew its stake in BioCryst Pharmaceuticals by 131.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock worth $62,000 after buying an additional 5,912 shares during the last quarter. JGP Global Gestao de Recursos Ltda. purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $64,000. Seven Eight Capital LP acquired a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $57,000. Finally, Natixis grew its position in shares of BioCryst Pharmaceuticals by 400.6% during the first quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 9,350 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BCRX shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a research note on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $14.00.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.